Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) will launch personalized CBD anti-tumor tests for people suffering with cancer. The diagnostic tests use liquid biopsies of cancer patients. It uses CTC technology that accumulates cancer cells from cancer patients’ blood samples, and assesses their sensitivity to CBD compounds together with conventional chemotherapy drug.
The study data allow physicians to better plan their decisions as they can personalize patient data and support evidence to prevailing market treatments. Dr. Eyal Ballan, who is the Chief scientist of Cannabics, reported that they intend to make use of the natural medicinal properties of cannabis. This will be achieved using the diversity of active composites to fight cancer in its demonstration in each individual patient.
Through an exclusive assignment with Cancer Hope Israel, which focuses on providing a comprehensive check of the chemotherapy and unique biological drug’s effectiveness, Cannabics will provide its patented cannabinoid based compounds to be tested in their anti-tumor properties. The company plans to start commercialization process in March, when 10 initial patients’ liquid biopsies will be assessed deploying this technology.
Cannabics objective is to spread this service to cancer patients across Canada, Europe and the U.S., under resident medical cannabis protocols in each country and state. This target has to be achieved by the close of the year. Itamar Borochov, the CEO, commented that they mark the first firm in the world to offer personalized CBD anti-tumor diagnostics to cancer patients. The company is excited to be pioneers in the segment of cannabis and personalized cancer therapies.
Cancer Hope Israel comes in the list of a Personalized Oncology Center that shows and provides state-of-the-art diagnostics for personalized cancer treatment. Cancer Hope collaborates with international leaders in cancer diagnostics and medicinal solutions in endeavor to promote personalized oncology therapy as standard treatment. As part of their vision they intend to bring together oncology experts with latest diagnostics for best patient care.